📊 HG&W Review Report: Amgen Inc.

1. Introduction & Legacy

Founded in 1980 as Applied Molecular Genetics, Amgen has grown into one of the largest independent biopharmaceutical companies in the world, headquartered in Thousand Oaks, California. The name “Amgen” reflects its genetic research heritage, symbolizing its deep roots in molecular biology.

2. Market Position

Amgen ranks 18th globally among biomedical companies by revenue, with annual revenues exceeding $28 billion (2023). Its therapeutic portfolio focuses on some of the world’s most pressing health challenges, spanning oncology, cardiovascular disease, nephrology, bone health, and autoimmune conditions.

3. Innovation & R&D Leadership

Research and development are at the heart of Amgen’s business model. The company invests over $4 billion annually in R&D, leveraging advanced genomics and biotechnology platforms. Key innovations include biologic therapies and biosimilars designed to target specific molecular pathways.

4. Global Reach

Amgen operates in 100+ countries, delivering therapies to millions worldwide. This global footprint ensures both scale and resilience, positioning the company as a leading player in the international biopharma ecosystem.

5. Strategic Acquisitions & Partnerships

Amgen’s expansion has been fueled by high-impact acquisitions:

• Otezla (2019) – bolstered Amgen’s inflammation portfolio.

• Horizon Therapeutics (2023) – expanded Amgen’s rare disease pipeline.
  These moves showcase a strategy of acquiring complementary assets to strengthen its therapeutic offerings.

6. Sustainability & ESG Commitments

Amgen has pledged to achieve carbon neutrality in operations by 2027, with investments in sustainable manufacturing and supply chain innovation. It also champions global medicine access initiatives, aiming to balance profitability with social responsibility.

7. Future Outlook

Amgen faces increasing competition in the biosimilars market but remains well-positioned with its strong pipeline, R&D investments, and focus on personalized medicine. Its dual strategy of innovation and acquisition ensures long-term growth and resilience.